RainSure Scientific Secures Tens of Millions in Series A Funding Led by Yuansheng Venture Capital to Accelerate Leadership in Digital PCR Market

VCBeat (WeChat ID:VCBeat) learned at the first opportunity that Suzhou RainSure Scientific Co., Ltd. (hereinafterAbbreviation“RainSure SCIENTIFIC”) announced the completion of its tens-of-millions-yuan Series A financing round in Suzhou Industrial Park, with this round led by YuanBio Venture CapitalVenture CapitalLed by the lead investor, with follow-on investments from existing shareholders Mingshi Capital and Volcanics Venture.

According to reports, this round of financing will be used for the research and development of digital PCR systems and supporting reagent kits, as well as the establishment of sales channels. Previously, RainSure Scientific had successively received investments from ZhenFund, Volcanics Venture, and Mingshi Capital.

RainSure SCIENTIFIC, established in October 2017, is committed to the mission of innovation, intelligent manufacturing, and serving health. It is dedicated to driving the innovative application of leading technologies, including digital PCR, across broader health sectors such as medical healthcare, food safety, and inspection and quarantine.

Its founding members all hold Ph.D. degrees from top-tier universities, including Ivy League institutions in the United States. They have long served at highly reputable biotechnology companies within the industry, where they participated in and led the development of multiple well-known products. As such, they possess a solid academic background and extensive industrial experience.

Currently, RainSure SCIENTIFIC has established a comprehensive team structure, building talent pipelines across product R&D, manufacturing, regulatory registration and certification, and sales.

According to reports, RainSure SCIENTIFIC has completed the digitalCommercial Development of PCR Products, launched includingTwo generations of digital PCR systems, including DropX-1000 and DropX-2000.

Meanwhile, RainSure SCIENTIFIC took the lead in launching overRainSure SCIENTIFIC has developed 50 proprietary digital PCR assay kits, covering detection of tumor point mutations (including non-small cell lung cancer, colorectal cancer, melanoma, breast cancer, gastric cancer, and other cancer types), gene fusions, and copy number variations. The company is actively expanding its clinical diagnostics portfolio, including tumor companion diagnostics and liquid biopsy.Track, already approvedTwo Medical Device Product Registration Certificates.

According to the introduction, the RainSure DropX-2000 system launched by RainSure Scientific consists of two parts: an automated sample processing system and a biochip reader. The automated sample processing system requires no additional pressure source or PCR amplification equipment. When used with the RainSure RC2000 integrated chip, it automates sample processing (droplet generation and amplification). The biochip reader can automatically detect and analyze data, featuring four fluorescence channels to enable a wider range of reagent kit detection combinations.

RainSure SCIENTIFIC DropX-2000 Digital PCR System

OverviewThe RainSure DropX-2000 system, which requires operators to perform only manual sample loading and chip transfer, is among the most highly automated digital PCR products currently on the market. It is also the only four-fluorescence-channel digital PCR instrument formally available for sale at present. RainSure Scientific is closely responding to customer needs by accelerating the development of a fully automated, highly integrated digital PCR system, addressing critical clinical pain points and enabling a transformative upgrade in the clinical application of molecular diagnostics.

RainSureThe DropX series currently has multiple users in China, including the Chinese Academy of Sciences. The company’s user base is continuously expanding, now covering leading biopharmaceutical companies, universities and research institutes, IVD enterprises, hospitals and third-party medical laboratories, centers for disease control and prevention, and entry-exit inspection and quarantine agencies.. Meanwhile, at a domestic and international digital event hosted by a certain university in ChinaIn performance benchmarking of PCR instruments, the RainSure DropX series has demonstrated performance comparable to that of leading international brands. Another product from RainSure Scientific, its flow cytometer, is also highly excellent.

Currently, microfluidic sample injection systems on the market include syringe pumps, peristaltic pumps, and piston pumps. These systems are inadequate for controlling fluids at the nanoliter scale, often exhibiting issues such as hysteresis, long stabilization times, poor repeatability, and pulse effects. The constant-flow microfluidic injection control method achieved by syringe pumps offers only a limited number of control channels; if more than four channels are required, multiple parallel syringe pumps must be employed, resulting in high costs and substantial equipment footprint.

The PG-MFC Flow Controller, developed by RainSure SCIENTIFIC’s R&D teams in China and the United States, is a microfluidic pressure injection system based on precise pressure control. The PG-MFC Flow Controller achieves accurate, stable, and pulse-free pressure output by regulating the pressure source. This approach facilitates system integration, requires minimal space, and ensures that the fluid does not contaminate the system.

The PG-MFC Microfluidic Controller integrates pressure and flow rate control, providing rapid, stable, pulse-free pressure output. When connected to an external flow sensor, it also delivers precise and stable flow rate control. Therefore, this fluidic controller is suitable for both industrial product development and scientific research applications.

The product is currently performing well in the market, with representative clients including renowned domestic and international universities such as Georgia Institute of Technology, Virginia Tech, University of California, Irvine, University of Ottawa, ShanghaiTech University, Shanghai Jiao Tong University, and The University of Hong Kong.

RainSure SCIENTIFIC Microfluidics Product Series

RainSure SCIENTIFIC's digital PCR products feature complete independent intellectual property rights,Patent layout has been established. RainSure SCIENTIFIC revealed:“We strategically align our patent portfolio with market dynamics, having filed relevant product patents in China and the United States. Currently, our primary focus is the domestic market; however, we plan to actively pursue patent applications in Europe, Southeast Asia, and other regions to strengthen the patent protection of our core technologies.”。”

Following this round of financing, RainSure SCIENTIFIC will continue to drive the implementation of digital PCR application solutions in clinical diagnostics, scientific research, food safety, and other fields. The company will further strengthen its clinical product R&D and registration team as well as its marketing and sales team, delivering innovative solutions to customers.

RainSure SCIENTIFIC Reveals:“In the future, we will develop an all-in-one digital PCR system that is more integrated, compact, and portable. In terms of test kits, we will also actively expand into fields such as clinical diagnostics and food safety, developing products that meet market demands.”Application-side products.”

In terms of its team, RainSure SCIENTIFIC has recruited several seasoned industry veterans with extensive experience in the operation and management of large-scale diagnostic instruments and equipment., while actively building“Direct Sales + Distributor” Network: Collaborating with Industry Peers to Rapidly Enter the Domestic Market.

RainSure SCIENTIFIC stated:“Going forward, we hope to become a China-basedA Global Leader in Life Sciences. Our short-term goal is to secure a significant voice in the Chinese market by leveraging the performance and quality advantages of our products, as well as our superior corporate services.”

Dr. Wang Yaqi, Chairman of RainSure SCIENTIFIC, stated, “RainSure SCIENTIFIC continues to strategically position itself in the digital PCR sector, firmly believing in its significant market position within the field of molecular diagnostics. Leveraging a strong R&D team and adhering to independent innovation, the company has established a comprehensive digital PCR ecosystem encompassing innovative professional digital PCR instruments, compatible consumables, universal reagents, customized reagent development, and digital PCR testing services, which have been widely acclaimed by customers. Furthermore, the revenue achieved by the company in the first half of 2019 represented a more than threefold increase compared to the full year of 2018.”

“YuanBio Venture Capital, the lead investor in this round, is one of China’s most professional investment institutions in the life sciences sector, with a portfolio comprising leading enterprises across various fields. Upon the completion of this strategic investment, we are confident that”Partnering with YuanBio Venture Capital to Advance Digitalization More Effectively and EfficientlyPCR Ecosystem Development.”

Lin Yi, Managing Partner of YuanBio Venture Capital, stated:“YuanBio Venture Capital has consistently focused on innovation in China’s digital PCR sector. Over the past decade, the characteristics of digital PCR, such as absolute quantification and high sensitivity, have been applied in scientific research.”Shine brightly in the field. DigitalSince the commercial launch of PCR products in 2011, they have rapidly gained adoption among research institutions and corporate users, owing to their clearTechnological Advantages Gradually Replace Quantitative FluorescencePCR products."

“Digital PCR instruments and test kits were first approved by the U.S. FDA for clinical diagnosis of hematologic diseases in 2019.”Market Means NumbersThe clinical application of PCR will gradually enter a phase of large-scale adoption. The initial popularization of real-time quantitative PCR (qPCR) technology in China gave rise to a cohort of outstanding benchmark enterprises, such as Daan Gene. Much like the trajectory of qPCR, the field of digital PCR (dPCR) is poised to produce leading companies that will spearhead the next generation of molecular diagnostic applications.Market.”

“RainSure SCIENTIFIC is a leading enterprise in the field of digital PCR in China, possessing complete independent intellectual property rights,”We fully recognize RainSure SCIENTIFIC’s innovative vitality and its product-first craftsmanship. Through this round of investment and leveraging YuanBio Venture Capital’s ecosystem capabilities in the life sciences sector, we aim to empower RainSure SCIENTIFIC to accelerate its market expansion and product commercialization.”

RainSure Scientific was established in 2017. Since its inception, RainSure Scientific has adhered to the philosophy of “Global R&D, Intelligent Manufacturing in China,” taking “Innovation, Intellectual Creation, Excellence in Life” as its mission, and focusing on frontier technological innovation and product development in the broader health sector.

Currently, RainSure Scientific’s product portfolio encompasses two major segments: digital PCR systems and microfluidic solutions. The company has established production bases in Suzhou (Suzhou RainSure Biotechnology Co., Ltd.) and the United States.

RainSure SCIENTIFIC has received widespread international acclaim, earning numerous honors including the Championship in the Western U.S. Division of the China Association for Science and Technology’s inaugural Overseas Entrepreneurship Competition, recognition as a Leading Entrepreneurial Enterprise in Suzhou Industrial Park (2018), a Gusu Angel Investment Enterprise (2018), an approved project unit for Jiangsu Province’s Innovation and Entrepreneurship Program for Returned Overseas Chinese Scholars (2018), and inclusion in Jiangsu Province’s High-Tech Enterprise Incubation Pool (2019). The company has also secured investments from renowned domestic and international institutions such as ZhenFund, Volcanics Venture, and Mingshi Capital.

YuanBio Venture Capital is an investment firm focused on the early and growth stages of the healthcare sector. Headquartered in Suzhou BioBAY, it maintains a global reach. The firm currently manages approximately RMB 5 billion in assets and has completed investments in over 60 high-quality projects, primarily spanning new drug development, medical devices, in vitro diagnostics (IVD), and healthcare services. It has delivered substantial investment returns and has been repeatedly recognized as one of the Top 10 venture capital funds in China’s healthcare sector and among the most active healthcare investment institutions in China.

YuanBio Venture Capital brings together a team of seasoned professional investors and world-class scientific advisors, boasting extensive experience in entrepreneurship, venture capital, and corporate operations within the biopharmaceutical industry and beyond. Leveraging its focused strategy and abundant industry resources, YuanBio Venture Capital is committed to becoming one of China’s most successful healthcare and pharmaceutical venture capital funds.